Showing results (51-60 of 710) with videos related to
Sort By:
Pageof 71
Cancer Research|April 22, 2014
Enhancement of the T-cell armamentarium as a cell-based therapy for prostate cancerW Nathaniel Brennen, Charles G Drake, John T IsaacsCancer Immunology Research|December 7, 2014
PD-1 blockade in renal cell carcinoma: to equilibrium and beyondLauren C Harshman, Charles G Drake, Toni K ChoueiriClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2020
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line SettingDavid H Aggen, Charles G Drake, Brian I RiniNature Reviews. Clinical Oncology|November 20, 2013
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancerCharles G Drake, Evan J Lipson, Julie R BrahmerCurrent Oncology Reports|August 19, 2018
Immunotherapy in Prostate Cancer: Teaching an Old Dog New TricksMichael C Comiskey, Matthew C Dallos, Charles G DrakeInternational Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomasJing Zeng, Alfred P See, Jillian Phallen, et al.Cancer Cell|April 28, 2023
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulatorsAleksandar Obradovic, Casey Ager, Mikko Turunen, et al.Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2024
Therapeutic implications for the PD-1 axis in cerebrovascular injuryJames Feghali, Christopher M JacksonThe Journal of Clinical Investigation|August 15, 2022
Supercharged chimeric antigen receptor T cells in solid tumorsAyush Pant, Christopher M JacksonJournal of Immunology (Baltimore, Md. : 1950)|January 10, 2018
Inhibitors of the PD-1 Pathway in Tumor TherapyMartin W LaFleur, Yuki Muroyama, Charles G Drake, et al.Pageof 71